2023-01205. Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals Inc.  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Janssen Pharmaceuticals Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2023. Such persons may also file a written request for a hearing on the application on or before March 24, 2023.

    ADDRESSES:

    The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public Start Printed Page 4020 view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.33(a), this is notice that on December 1, 2022, Janssen Pharmaceuticals Inc., 1440 Olympic Drive, Buildings 1-5 & 7-14, Athens, Georgia 30601-1645, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

    Controlled substanceDrug codeSchedule
    Methylphenidate1724II
    Hydromorphone9150II
    Hydrocodone9193II
    Oripavine9330II
    Thebaine9333II
    Tapentadol9780II

    The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. No other activities for these drug codes are authorized for this registration.

    Start Signature

    Matthew Strait,

    Deputy Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2023-01205 Filed 1-20-23; 8:45 am]

    BILLING CODE P

Document Information

Published:
01/23/2023
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2023-01205
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 24, 2023. Such persons may also file a written request for a hearing on the application on or before March 24, 2023.
Pages:
4019-4020 (2 pages)
Docket Numbers:
Docket No. DEA-1134
PDF File:
2023-01205.pdf
Supporting Documents:
» Bulk Manufacturer Application - Janssen Pharmaceuticals (2023-01205) - DEA1134